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Executive Summary
▪ LeMaitre Vascular Inc. is a US-based manufacturer of devices for peripheral vascular
surgery. They directly target the vascular surgeon via sales representatives and offer
primarily products for open vascular surgery
▪ 2017 is expected to be a record year, with sales reaching $ 101M in 2017 (5-year CAGR of
12%). LeMaitre also made its cost structure more efficient, leveraging the bottom line
(EBITDA 5-year CAGR of 32%) and is highly cash-generative
▪ The global peripheral vascular device market is growing at a CAGR of 5-7%, driven by
increased prevalence of peripheral vascular disease, demographic aging trends and
healthcare improvements in Emerging Markets
▪ In the PVD market, LeMaitre has the competitive advantage of being the only player with a
clear focus on the vascular surgeon, having the most comprehensive portfolio and being
quality leader in several niche products
▪ Executing this strategy will lead to an increase in revenue from $
101M in 2017 to $ 184M in 2022 (CAGR 13%). EBITDA will increase
from $ 24M in 2017 to $ 54M in 2022 (CAGR 16%), as EBITDA
margins improve from 24% to 29%
▪ LeMaitre will be acquired for an entry EV/EBITDA multiple of 13.5x,
i.e. for an EV of $ 347M. No Multiple Arbitrage will be assumed
▪ Total leverage will be 6.0x EBITDA, hereof two senior term loans
(4.5x) and a subordinated loan (1.5x), supported by a RCF
▪ LeMaitre’s management will buy into the new capital structure and
own a total of 18.4 % of the ordinary shares as well as 11.8% of the
FRI
▪ Main equity value drivers are organic sales growth (50%), margin
expansion (26%), deleveraging (13%) and non-organic growth (11%)
▪ The aspired exit through a strategic sale in 2022, for an exit EV of
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LeMaitre and the Peripheral Vascular Device (PVD) market
▪ The investment thesis is based on three main pillars: portfolio expansion, further
internationalization and operational efficiency
▪ The goal is to build a more comprehensive portfolio covering all the surgeons’ needs,
incorporating also endovascular in addition to open surgery. The portfolio will increase from
15 to ~20 product lines through acquisitions of single product lines, supported by R&D efforts
▪ Top-line growth will also be driven by increased internationalization. Especially developed
Asia and the BRIC countries offer untapped market opportunities for LeMaitre, which will
be explored
▪ Regarding operational efficiency, the centralization of operations of externally
manufactured products to the main facility, improvement of inventory management and
supplier relationships will be targeted
Value Creation and Business Plan
Deal structure, Returns & Exit
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Company Overview
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LeMaitre Vascular Inc. is a US-based manufacturer of devices for peripheral 
vascular surgery
▪ LeMaitre is a global leading
provider of devices used by
vascular surgeons to treat
peripheral vascular diseases
(PVD)
▪ Peripheral vascular disease is
any disorder affecting the
circulatory system apart from
brain and heart, such as
thrombosis and embolisms
▪ Designs, manufactures and
markets disposable and
implantable vascular devices
for use in both open vascular
surgery and minimally invasive
endovascular procedure
▪ The company’s growth has
been achieved through a direct
sales model, currently with 89
sales representatives in 21
different countries
▪ Its 397 employees are spread
across 9 offices in four different
continents and the worldwide
market size for its core
products is $870 Million
Company description Business strategy
Call Point:
Product selling and 
offering are directed to 
vascular surgeons to 





Leading position in niche 
products and services 
segments. High selling prices 
and higher market share due to 
the lack of competition and 
differentiated features with 
consistent quality
Growth Platform:
Acquisition and development 
in complementary vascular 
devices to expand its offerings 
and increase its technological 
features
High-level financials
Guidance for 2017 (after Q3):
Sales: $101M (+13% vs. ‘16)
Op Income: $20.9M (+43% vs. 
‘16)
Net Income: $16.9M (+60% vs. 
‘16)
EPS: $0.84 (+53% vs. ‘16)
EBITDA: $24.7M (+24% vs. ‘16)



























No other company 
covers the whole 
spectrum of vascular 
devices and procedures
Leading position in 
niche markets
#1 or #2 market share in 
12 of the 15 vascular 
product lines
M&A expertise
1 acquisition per year, 
on average, and 75% of 
sales are coming from 
those
Outside the radar of 
biggest Medtech firms
97% of LeMaitre’s 
revenue comes from 
markets < $125M
1 2 3 4
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LeMaitre is a worldwide provider of a broad range of equipment for vascular 








% of overall sales in 2017
LeMaitre offers 33 products across 15 product lines. Open Non-Biological: 9; Open 

































Weight in sales: As of June ‘17 these 8 products represented more than 75% of sales
%









Vascular procedures are required when the blood vessel blockage is significant. 
Vascular surgery allows the blood to bypass the narrow area through vein grafting
▪ PVD affects over 20 million people worldwide and typically goes undetected 










▪ The vascular surgeon (~5000 worldwide certificated) plays a key role in the
treatment of PVD and is the main customer of peripheral vascular devices
▪ Main diseases: Deep vein thrombosis, peripheral aneurysm, peripheral arterial
disease (most common type), Pulmonary Embolism, etc;
▪ Aging population, unhealthy lifestyle habits, blood related diseases
LeMaitre total addressable market is expected to increase from $0.9B to $1.1B 
from 2017 to 2022
▪ LeMaitre competes with both small niche players and global Medtech market leaders
▪ The firm does not compete with any firm in all product lines, as it is the only
company with a strong focus on vascular surgeons
Non-biological products 
used in open vascular 
surgery
Open non-biological Open biological Endovascular
Devices used in open 
vascular surgery with 
properties derived from 
animal and human sources
Minimal invasive surgery 
devices that allow vessel’s 
internal repairing
LeMaitre’s last 5 years 
sales CAGR: 6% 
LeMaitre’s last 5 years 
sales CAGR: 46% 
(mainly due to XenoSure)
LeMaitre’s last 5 years 
sales CAGR: -4% 
* Deep dive in products overview appendix slides
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With a strong sales reps model, LeMaitre made 19 acquisitions in 19 years with a 














▪ Corporate HQs: Burlington, US 
▪ International HQs: Germany
▪ Asian HQs: Japan
▪ Sales offices: Spain; Italy 
Canada; China; Japan; Australia




Number of sales reps per region#
Direct sales model through sales representatives
▪ Allows to cross-selling and implementation of high selling prices
▪ Incentivized on gross profit goals
▪ 89 sales reps in 21 countries- LeMaitre adds ~5 sales reps per year
▪ The number of sales reps increased from 40 to 100 in the last 10 years, with
an average turnover rate of 1.18%
▪ This channel represented between 85-95% of revenue during the last years
▪ Germany: Over the first 10 years of the sales reps model implementation,
LeMaitre achieved a 58% CAGR, (compared with 41% in France where no
sales reps were added in the same timeframe)
























Acquisitions and key products/services
Year Acquisition Product Acquired
Post-acquisition 
sales CAGR
2016 RestoreFlow Human tissue cryopreservation 12%
2016 ProCol Biological vascular graft 15%
2015 Tru-Incise Valvulotomes N/A
2014 Angioscope Fiberoptic catheters N/A
2014 Xenotis Pty Biosynthetic grafts/OmniFlow 34%
2013 Trivex Powered phlebectomy system 9%
2013 Clinical Instruments Carotid Shunts and Embolectomy Catheters N/A
2012 XenoSure Biological patches 48%
2010 LifeSpan ePTFE grafts 5%
2007 Biomateriali Polyester grafts and patches -1%
2007 UnBalloon Technology Stent graft modeling catheters N/A
2007 Vascular Architects Remote endarterectomy devices 3%
2007 Vascular Innovations Contrast injector -1%
2005 Endomed Stent grafts N/A
2004 VCS Clip Vessel closure system 11%
2003 Credent Polycarbonate grafts N/A
2001 Ideas for Medicine
Carotid shunts, balloon catheters and laparoscopic 
cholecystectomy devices
8%
1999 Vermed Balloon catheters 8%
1998 Whittaker Screen Printing Radiopaque tape manufacturing operations 12%
LeMaitre’s acquisition strategy is based on acquiring complementary products:
• The goal is having the most comprehensive portfolio of vascular products and being
able to offer the full set directly to surgeons
75% of total current revenue is obtained thorugh previously acquired product lines
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LeMaitre’s management is composed of a cohesive and fully experienced team 
and ownership has become much more diluted
Chairman & CEO: George W. LeMaitre, 52
LeMaitre Vascular’s CEO and member of the Board of Directors since 1992,
serving as its Chairman since 2004. Previously, Mr. LeMaitre worked at
Lehman Brothers, McCown De Leeuw and the Connecticut National Bank.
Mr. LeMaitre received a B.A. in History & an M.B.A. from Stanford University.
CFO & Board Director: Joseph J. Pellegrino, 52
LeMaitre’s CFO since 2007. Mr. Pellegrino joined LeMaitre as its Executive
VP of Finance, in 2005. Mr. Pellegrino is also a director of Access Vascular,
Inc., a medical device company. He has gained extensive experience in
operations and finance with prior employers and earned his B.A. in
Economics & M.B.A. from Harvard Business School.
President & Board Director: David B. Roberts, 53
LeMaitre’s President since 2007, but joined LeMaitre in 1997 as VP of
Business Development and was promoted to CFO from 2000 to 2007. Mr.
Roberts received a B.A. in Business Economics and History from Brown
University and an M.B.A. from the Stanford University.
61% 77.8%
Younger than 50 years old Over 10 years with LeMaitre
Top Management Management facts
President, International Operations: Peter R. Gebauer, 63
LeMaitre’s President of International Operations since 1997. From 1980 to
1996, Mr. Gebauer worked at IMPRA, Inc., a manufacturer of ePTFE
vascular grafts. Mr. Gebauer received a B.S. in Business from the University
of New Hampshire.
▪ The graph represents the TOP 5 Institutional Investors, as well as George
LeMaitre (unique individual with an ownership > 2%)
▪ LeMatre’s ownership evolution, from 2012-2017:
▪ ~87% held by institutional owners (compared to ~20% in 2012)











Dimensional Fund Advisors LP
Vanguard Group
Conestoga Capital Advisors
AWM Investment Company Inc
Others
Senior Vice President & General Counsel: Laurie A. Churchill, 46
LeMaitre’s Senior VP and General Counsel since 2016. Ms. Churchill joined
LeMaitre in 2012 as Director of Legal Affairs. Ms. Churchill earned a B.A. in
English Education from the University of North Carolina at Chapel Hill and a
J.D. from New York University School of Law.
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*There is legislation in the U.S. House of Representatives that would put the medical device tax on another hiatus for more 5 years.
Sources: Annual Report, Earnings Calls, Bloomberg, Global Data Report, Craig Hallum and Barrinton initiation of coverage. 2017 values reflect full-year guidance provided in Q3 Earnings Cal and our estimates.
LeMaitre was able to make its cost structure more efficient
products or accumulated growth of these (latter is considered as organic growth in the table)
▪ During this period LeMaitre was able to increase the weight of international sales in total sales
(from 33% in 2012 to 40% in 2016) while also increasing revenues in Americas
▪ Prices have been increasing almost 5% every year since 2012
▪ No product accounts for more than 25% of total sales
▪ Began a restructuring plan in ’14, which included workforce reduction
(~10%), centralization of manufacturing and other cost-cutting measures
▪ Sales & Marketing went from 37% of sales to 29% (‘12-’16). This was mainly
due to leverage of existing direct sales force, boosting sales
▪ R&D department focuses mainly in improving existing products. R&D
expenses went down from 9% to 7% of sales
▪ Other operating expenses include one-offs such as restructuring charges and
gains on divestitures. From ’13 -‘15 was included a Medical device excise tax*




LeMaitre managed to consistently grow both its top and its bottom line 
throughout the last years
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▪ Most products are manufactured in LeMaitre’s headquarters (Burlington). By the end of 2016, of all
the 19 acquisitions, only 4 products were manufactured by third-parties and 2 of them were
expected to be relocated to Burlington by the end of 2018
▪ Also relies on single and limited-source suppliers for several of its key product components (raw
materials, antibiotics, etc.). However, never experienced material disruption in the adequate supply
▪ COGS consists primarily of manufacturing personnel, raw materials and components, depreciation
of property and equipment, and other allocated manufacturing overhead, as well as freight expense
2
▪ “Non organic” relates to sales from acquired
operations in the 12 months following the
acquisition. LeMaitre estimates that 75% of








Millions $ 2012 2013 2014 2015 2016 2017 E
Revenues 57 65 71 78 89 101
% growth 14% 10% 10% 14% 13%
Open non-biological 45 50 54 56 59 61
Open biological 5 8 11 17 24 35
Endovascular & Others 6 6 6 6 6 5
Gross Profit 41 45 48 54 63 71
% gross margin 72% 70% 68% 69% 71% 70%
Operating Expenses 37 41 42 43 47 50
% growth 11% 4% 1% 9% 8%
SG&A 32 35 36 37 40 43
R&D 5 5 5 5 6 7
Other 0 1 1 0 0 0
EBITDA 6 7 10 15 20 25
% margin 11% 11% 14% 19% 22% 24%
2
3
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Millions $ 2012 2013 2014 2015 2016 2017F
EBIT 4.2 4.5 6.3 11.5 16.3 20.7
(-) Interest and Foreign currency gain/loss 0.2 0.2 0.0 0.1 0.1 0.0
(-) Taxes 1.4 1.1 2.4 3.7 5.7 6.6
Depreciation & Amortization 2.2 2.8 3.3 3.4 3.6 4.0
(-) Change in Working Capital 2.7 2.8 3.9 0.7 -0.4 2.4
Accounts Receivable 0.6 1.2 0.7 1.9 0.9 0.1
Inventory and other deferred costs 3.7 2.2 2.7 -0.6 0.1 0.2
Prepaid expenses and other assets -0.3 0.2 -0.6 2.0 -1.5 2.1
Accounts payable and other liabilities -1.4 -0.9 1.1 -2.6 0.1 0.1
Stock-Based Compensation 1.2 1.2 1.1 1.0 1.7 1.2
Deferred Income Taxes 0.3 0.3 -0.1 0.2 0.1 0.0
Other Non-Cash Adj 1.1 0.7 1.2 -0.2 0.6 0.7
Operating  Cash Flow 5 5 6 11 17 18
(-) Maintenance CAPEX 1.3 2.9 1.2 2.3 2.8 3.0
Divestitures 0.5 0.0 0.0 0.4 0.0 0.0
(-) Expansion CAPEX (Acquisitions) 4.4 3.3 6.6 1.6 14.4 0.0
Investment  Cash Flow -5 -6 -8 -3 -17 -3
Other Non-Cash Adj
Main drivers of NWC have been changes in inventory
A growing business in combination with a debt-free balance sheet, resulted in 
growing OCFs and high cash conversion
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▪ LeMaitre performed acquisitions every year since 2012 and most of these
recent acquired companies had excessive inventory
4
▪ A significant amount of previous years Purchases of property and equipment is
associated to the expansion of the company’s headquarters, manufacturing
equipment and leashold improvements.
7
▪ These are forms of equity compensation and are recognized as an expense
based on fair value assumptions over which the stock options will be
outstanding, without necessarily having existed a cash movement
5
▪ Includes items such as Provisions for deferred taxes, for doubtful accounts, for
inventory write-downs, Gains on divestutures, on foreign currency transactions, etc.
▪ Most of the adjustments are related to Inventory write-downs, which as mentioned
before, are due to excessive inventory from previous acquisitions
6
▪ 4 of the 8 acquisitions completed in the last five years are related to the open biological
segment, which shows its recent effort to grow in this space
8






Mostly composed by Stock option awards and Restricted stock units
Maintenance CAPEX in the last years remained stable and low






















Market Size and Growth
Competitive Snapshot
LeMaitre Differentiating Factors
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PVD affects over 20 million people worldwide and typically goes undetected until a 




From 1997 to 2008, there was an increase of 22% vascular procedures for all
adults. Surgery may be required when the blood vessel blockage is significant:
Peripheral Vascular Disease (PVD)
Estimated to affect > 20 million people
worldwide.
Refers to any disease of the
circulatory system outside of the
brain and heart. It includes disorders
affecting blood vessels, veins and
arteries, which carry blood to organs,
limbs and head. Such disorders can be:
narrowing, obstructing
(arteriosclerosis), widening (varicose
vein) or weakening of such vessels.
Peripheral Arterial Disease (PAD) is the
most common type of PVD.
Sources: http://study.com/academy/lesson/vascular-spasm-causes-symptoms-lesson.html; http://www.grandviewresearch.com/industry-analysis/peripheral-vascular-devices-market; LeMaitre Annual Report 2016; Healthcare Cost and Utilization Project; Population-based analysis of 





















▪ Smoking, obesity or lack of 
exercise
▪ Diabetes and high cholesterol
▪ High blood pressure
▪ Heart disease
▪ Kidney disease
▪ Being over the age of 50
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Risk Factors
Vascular Bypass
▪ Only to perform both open surgical 
and endovascular procedures
▪ Main provider of peripheral arterial 
interventions
▪ Share of PV surgeries increased 
from 27% in 1998 to 43% in 2005
Role of Vascular Surgeon
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Deep dive in Market Overview appendix slides
PVD market: Major growth drivers are global demographic developments and 
improving healthcare conditions in Emerging Markets
Market driver Impact Description of the impact on the Peripheral Vascular Device market
Demographic trends
Increased incidents and 




Shift towards endovascular 
procedures
Improving quality of medical 
care in EM









▪ Global elderly population (>65 years) will rise from 600M in 2015 to 1.8B in 2060
▪ Personal healthcare (HC) spending for this group in the US is 3x the spending of a working-age person
▪ Number of people affected by PAD globally rose by 24% from 2000 until 2010
▪ Further increase expected, especially in low- and middle-income countries due to increased 
prevalence of traditional PAD risk factors and an aging and growing population
▪ Increased awareness of PAD boosts precautionary examinations and diagnosis rate 
▪ Unit growth of endovascular devices due to continuous evolvement of minimally-invasive procedures 
expected to continue
▪ Overall effect neutral, as devices for some open procedures stagnate in return
▪ Recent successful innovative devices, e.g. the drug-coated balloons (DCB), are increasingly
complex and sell for higher prices than elder product lines
▪ Advanced, state-of-the-art treatment methods are used in greater scale in EM
▪ Range of available treatment methods and devices for PVD in EM increases
▪ HC spending grows faster in Emerging Markets than in the rest of the world
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The peripheral vascular device market has historically grown at ~5% p.a. and is 
expected to grow at 5-7% p.a. in the upcoming years
Key Takeaways
▪ In the last 5 years, the total PVD market has grown from ~3.5 $B
to 4.5 $B globally (CAGR of 5%)
▪ The directly addressable segment of the market has grown at a
slower pace of ~3% p.a., because it is mainly composed of
open vascular devices, which grow slower than endovascular
devices
▪ Until 2022, the market is expected to keep growing at a CAGR
of ~5-7% globally
▪ Favorable demographic trends in developed markets and
economic and infrastructural developments in Emerging
Markets are key growth drivers
▪ Within the current TAM, the Open-Biological segment is
expected to grow the fastest
▪ The future size and growth of the addressable market will
depend on the development of LeMaitre’s product portfolio,
namely its future acquisitions
▪ If LeMaitre extends its portfolio more aggressively, e.g., by
acquiring several endovascular products, its TAM can increase



















Note: Market size and splits are estimations based on triangulation of several sources.
Sources: LeMaitre Annual Reports, Company Information, US Trade Organization, MarketsandMarkets Report on PVD 2016, Diagnostic and Interventional Cardiology (DAIC)  
Peripheral Vascular Device Market Size 2012-2022 (in $B) 
Total Addressable Market (TAM) for LeMaitre
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LeMaitre competes with two heterogeneous archetypes of competitors composed 
of small niche players and global MedTech market leaders
▪ LeMaitre focuses on breakthrough innovation in order to maintain product differentiation and
premium positioning. However, the company still produces some more commoditized products
▪ LeMaitre does not compete with any firm in all product lines (please see details in Appendix -
slide 53), as it is the only company with a strong focus on vascular surgeons and the most
comprehensive product offering of vascular devices
▪ Most products are inserted in markets which are too small for large companies to enter (more
than 95% of revenue comes from markets sized below $125M)
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Market Share
#1 or #2 Market Share in 12 of 14 Vascular Product Lines.
Competitors Breakdown
▪ Specialized niche market players like LeMaitre are characterized
by having smaller market caps (<1B$) and a more focused call
point (physicians)
▪ Global Medtech leaders have big caps (>10B$), enjoy economies
of scale and have a much broader customer base (GPOs)
Market 















































Source: Bloomberg; Company Presentation
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LeMaitre’s greatest differentiation factors are its direct sales force, its focus on the 
vascular surgeon and its high-quality product portfolio
Superior product portfolio
Sources: LeMaitre Annual Reports, Company Information, Canacoord, Craig-Hallum
Direct sales model and focus on vascular surgeon
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▪ Only player focused on vascular surgeons
▪ High reputation in the vascular space since it was founded by
vascular surgeon Dr. LeMaitre
▪ Well-known by all vascular surgeons through the valvulotome,
Lemaitre’s signature product, still globally used by surgeons
LeMaitre’s unique competitive advantage and high reputation is a consequence of the fact, that it understands vascular 







Superior material compared to conventional patches:
- Exceptional resistance to breaking under pressure
- Consistent thickness, allowing for tight quality control
- Lower rate or restenosis
More tailored to surgeons’ needs than competition:
- Majority of models not reusable, as surgeons prefer that
- Sharper and more effective at cutting valves
- 89% efficacy rate vs. 80-82% for key competitors
Superior safety characteristics compared to others:
- Usage of internal balloon fixation, reducing stress on the 
blood vessels [compared to traditional shunts]
- For non-balloon shunts, blood flow rate is 39-104% higher 
than for leading competitors
▪ Well-nurtured, direct relationships to surgeons as competitive
advantage
▪ Success less dependent on single sales persons, but rather on the
consistent contact between company and surgeon
▪ Direct communication channel to main influencers in purchase








































LeMaitre has an outstanding reputation in the vascular community. 
The direct sales force provides not only direct access to key purchase decision 
makers, but also valuable insights into the surgeons’ needs and product wishes
LeMaitre’s products are tailored to the vascular surgeons’ needs. 
Consequently, LeMaitre grew faster than the market in all its major product lines 
in the past.
18Nova School of Business and Economics | Master in Finance | January 2018 | Private Equity Challenge | Group 1 | LeMaitre Vascular, Inc.
The market characteristics and highly specialized nature of LeMaitre’s 
business allows for high pricing power
▪ Continuous demand for new and advanced medical
devices and supplies give the buyers limited power to
bargain
▪ Even though group purchasing organizations (GPOs)
account for nearly 2/3 of purchases of medical devices,
the medical staff strongly influences hospitals’ choice of
devices: LeMaitre’s call point
▪ Device manufacturers receive payments from healthcare
providers who typically rely on insurer reimbursements, which can
cover all or only part of the cost of these products (procedure based
rather than devices based). These insurers can be private or
governmental, such as Medicare and Medicaid in the U.S.
▪ Manufacturers like LeMaitre must continue to differentiate to prove
their devices are necessary and will allow for better procedural
outcomes
Sources: Mercer Capital; Euromonitor International, Company Presentation
▪ The Patients are one or
more steps removed from
interactions with
manufacturers and the
pricing of medical devices
▪ Focused call point
▪ High degree of specialization
▪ No direct competition
▪ Differentiated products
▪ Strong servicing
Consumers - Patients Payers / Third-Party Coverage – Government & Private InsurersConsumers – Surgeons & Hospitals
Device Manufacturer – LeMaitre
Provides LeMaitre with high pricing
power, which in turn has allowed it to
sustain high margins.




2012 2013 2014 2015 2016 2017
LeMaitre's Products Price Increase (in Direct 
Sales territories)
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Portfolio Expansion (Acquisitions & R&D) 
Internationalization Strategy
Optimization of Operations
Financial Forecast (Operating Model)
Risks
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LeMaitre is a highly profitable company with a track record of several years of strong top and bottom line growth and increasing free
cash flows. The firm is unlevered and has a strong balance sheet with a high cash position
LeMaitre is participating in the attractive peripheral vascular device market, which is set to experience years of strong growth due to
favorable global demographic developments and medical infrastructure build-up in Emerging Markets
Within the vascular device market, LeMaitre is uniquely positioned, being the only firm with a clear focus on vascular surgeons, where
it offers the most comprehensive product portfolio and being market leader in most of the niche markets it covers
LeMaitre has the potential to significantly increase its market share of the global peripheral vascular device market by expanding and
optimizing its product portfolio. The biggest untapped product opportunities lie in the endovascular and biological space, which can
be exploited via a targeted acquisition and R&D strategy
LeMaitre can increase its Total Addressable Market by intensifying its internationalization efforts. Accelerated internationalization
will be driven by an optimized distribution approach tailored by country, increased efforts on regulatory approvals and further
entries into new markets, e.g. BRIC countries and South Africa
Additionally, LeMaitre has the potential to improve its bottom line results through operational efficiency measures including further
centralization of manufacturing, discontinuation of less profitable product lines outside the strategic focus, renegotiating supplier













































LeMaitre is uniquely positioned in the attractive peripheral vascular device 
market and is poised for strong EBITDA growth in the upcoming years
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▪ Focus on niche markets, where LeMaitre
can be among market leaders
▪ Vascular surgeon as focused call point
▪ Focus on high-margin and high-quality
products
▪ Differentiation via superior quality and
portfolio breadth
▪ Products with regulatory approval
perspective in international markets
▪ Gradual portfolio enhancement towards
~20 product lines (today:15)
▪ Consider discontinuation of unsuccessful
products
▪ Careful, but consistent acquisition
strategy (1-2 per year)
▪ Addition of endovascular and further
open-biological products in line with
current niche strategy
▪ LeMaitre will be positioned as an established leader in the open vascular space with a strong brand recognition
and high reputation among vascular surgeons
▪ Thanks to its high-quality open-biological biologics segment and new complementary endovascular products, 
LeMaitre will offer the most comprehensive product portfolio to vascular surgeons
LeMaitre’s product portfolio will be enhanced by adjacent vascular surgery 
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Concrete implementation stepsTarget portfolio profile
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A focused acquisition strategy supported by continuous R&D efforts will drive 
future portfolio enhancements 
▪ Continuous efforts in improving existing products and driving innovation in the open vascular space
▪ Hiring of 1-2 R&D specialists with high endovascular experience and knowledge
▪ Keep overall R&D expenditure ratio stable on current levels initially, then steadily increasing towards 8% of sales (currently 7%)










▪ Selective purchase of specific
product lines rather than whole
portfolio of products
▪ Small- to mid-sized acquisitions in
order to spread risks
▪ Focus on adjacent products,
leveraging own expertise and brand
recognition
▪ If endovascular, consider bringing





▪ High-margin product line
differentiated by superior quality
▪ Niche market with less competition
from biggest players
▪ Market with future growth potential
▪ Technological proximity to
LeMaitre’s current products
▪ Complements current portfolio to
cover more treatment methods
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*More information about each one of these products in appendix, p. 55
Strategic approach Ideal target product Potential target that meet most criteria
23Nova School of Business and Economics | Master in Finance | January 2018 | Private Equity Challenge | Group 1 | LeMaitre Vascular, Inc.
LeMaitre currently sells directly in 21 countries and in another 39 via distributors, 








Japan Office & Direct Sales Local Difficult Low 7.1%1 Moderate/ High
Australia Office & Direct Sales 
Multinationals 
(80%) 2
Medium Moderate3 6%3 Moderate
Korea Distributors Mixed Difficult Low 13.8%4 Moderate











Easy9 Low (<20%) 10 15% (2016)8 Low








South Africa Distributors Multinational12 Easy Low 5.6%13 Moderate/ High
Sources: 1Markets & markets; 2Export.org; 3Euromonitor International; 4PR Newswire; 5Emergogroup; 6Abnewswire; 7Export.gov; 8Deloitte; 9Med City News; 10 Infosys; 11Pacific Bridge Medical; 12South African medical device industry association; 13Business Wire
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Among the untapped markets, developed Asia and the BRIC-countries are 
especially attractive for LeMaitre going forward
Endovascular Open Surgery Biological 
▪ Why: High and stable prevalence of
endovascular procedures and predominantly
performed by vascular surgeons rather than
interventional radiologists, i.e. in-line with
call point
▪ How: Distributors
▪ Why: High growth rates combined with less
stringent regulation and relatively low
customs duties
▪ How: Partnerships
▪ Why: Amongst the world’s largest markets
and LeMaitre already has a foothold in it.
There is also potential to take advantage of
pricing power (no customs duties)
▪ How: Acquisitions & Direct Sales
▪ Why: Largest medical devices market in
South America, where LeMaitre already has
a strong presence. Endovascular
procedures are highly prevalent .
▪ How: Direct Sales
▪ Why: XenoSure approval (~2018/19)
combined with Omniflow’s presence build
strong foundation for a large biological
foothold
▪ How: Acquisitions
▪ Why: World’s largest markets for
endovascular devices and LeMaitre is
already established there
▪ How: Maintain current marketing strategy
▪ Why: One of the world’s largest markets,
with the medical device industry growing at
very high rates
▪ How: Partnerships
▪ Why: It particularly welcomes medical
equipment with high-technology content











































▪ Why: Prevalence of open-surgery over
endovascular with high market growth
prospects
▪ How: Partnerships due to the requirement
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US Canada Brazil Europe NZ Australia Japan Korea China
% of Products Approved in Market* 95% 98% 69% 92% 92% 65% 54% 49% 25% 
*Based on Q3 2017 worldwide net sales by product line 
There is still a lot of room to expand even in the markets we are already present in, specially in the open biological segment, which is recent in LeMaitre’s portfolio. 
Consequently, this will also be true for the endovascular segment, which is completely new to the company
Regulatory Approvals
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Additional measures increasing operating efficiency and minimizing costs along 
the value chain will support LeMaitre’s bottom-line growth
Impact on Value Chain
Optimization of operations Sourcing Manufacturing Distribution
NWC
In the last five years LeMaitre had a worse performance than its comparables regarding the Cash Conversion Cycle.
Even knowing that many of its excessive inventory comes from acquired companies, the difference to its peers is
excessive and as a result we would start working on a plan to improve inventory management. Moreover, we
would use our increasing brand recognition to negotiate better payment conditions with suppliers
▪ Target: Increase Accounts Payable days by 3 each year and decrease Inventory Days by 10 days each year
Centralization
LeMaitre usually relocates new acquisitions to its HQs in Burlington, however there are still some product lines that
could be incorporated into Burlington:
▪ EndoRE – Currently produced by third-party
▪ TRIVEX – Currently produced by third-party
▪ RestoreFlow Allografts – Currently produced in Fox River Grove facility, for which LeMaitre did a 2-year lease at
the time of the acquisition (2016). Nevertheless, the preservation of human tissue does not need to be made in
any specific location and therefore, it could be relocated by 2018
General Costs
Analyzing comparables, we concluded that there should be the opportunity to reduce General & Administrative
expenses. While this item represented between 20% and 16% of LeMaitre’s sales in the last five years, for
company’s comparables these costs floated between 7% and 14%
Suppliers
LeMaitre does not have contractual arrangements with many of its suppliers and third-party manufacturers, thus
being free to keep looking for new ones or to negotiate prices with the current
Portfolio
We would recommend to discontinue some product lines, namely the ones with lower margins and least
differentiation. By doing this, LeMaitre could improve profitability and focus on the products that better fit its
positioning. To start we would look for general surgery devices, such as laparoscopic cholecystectomy devices
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Revenues are expected to increase with a CAGR of 12%, driven mainly by the 
Endovascular and Open Biological segments
In $M 2012 2013 2014 2015 2016 2017*
CAGR 
12-17
2018E 2019E 2020E 2021E 2022E 2023E 2024E
CAGR 
17-24
Open non-biological 45 50 54 56 59 61 66 73 78 84 90 98 104
(YoY) 12% 7% 3% 7% 2% 8% 11% 8% 8% 8% 9% 6%
Open biological 5 8 11 17 24 35 41 48 53 62 69 78 87
(YoY) 50% 41% 53% 45% 44% 19% 15% 12% 16% 12% 12% 12%
Endovascular & others 6 6 6 6 6 5 10 14 19 21 24 27 30
(YoY) -2% -2% -5% -7% -2% 95% 38% 32% 12% 13% 12% 11%
Total 57 65 71 78 89 101 118 135 151 167 184 203 221






Open non-biological:          Price 
▪ Exploiting existing pricing power in US and increasing pricing power in
EU would allow for annual price increases of ~4-5%
Open biological:          Volume
▪ Highest growth segment and already submitted for new approvals
▪ Double-digit growth in Open Biological (10-16%), due to new products
gaining traction and regulatory approvals in additional countries
▪ Total increase from $35M in 2017 to $69M in 2022
Endovascular:          Non-organic
▪ Since LeMaitre is less established in the endovascular space and R&D
results are difficult to predict, the fastest way to grow is via acquisitions
▪ Assumed 6 acquisitions in the next 5 years (sized between $2-5M in sales),
3 of them in the endovascular segment (one each year, from ‘18 to ’20)
• 2017 values reflect full-year guidance provided in Q3 Earnings Call; Sources: Operating Model, LBO Model, Earnings Calls, Company Information
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Geographical drivers
▪ Growing fast over the years due to getting several approvals (33 in 2015)
▪ Intensified distribution in South Africa in 2021 is expected to boost growth
Americas & Europe:          Endovascular 
▪ Driven mainly by acquisitions of endovascular devices (U.S. – 2018/19 & EU - 2020)
▪ Establishing sales representatives in Brazil
▪ Overall slowdown trend over the years
Asia & Pacific Rim:          Open biological
▪ Driven by open biological: Approval of Xenosure in AU; Acquisition of biological device
in Japan in ‘21; Approvals in China, Korea, Japan and Taiwan predicted by firm for ‘22
▪ Partnerships in Russia, China and India mitigate the company’s slowdown in open
non-biological sales expansion. Each expected to increase SG&A costs by $0.4M in
the first year of the partnership and growing by 9% in the following years
Rest of the World:          Open non-biological
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LeMaitre leverages its bottom line by controlling G&A costs and increased 






Subject to two conflicting main influences: new dilutive acquisitions are dragging margins down each year, while the core business (including past acquisitions)
improves margins due to economies of scale and advanced integration and centralization. Also influenced by the geographic and product mix
Decreasing in % of Sales despite increase in absolute terms. Increase driven by hiring of additional sales reps (~15 in 5 years); intensified marketing campaigns
abroad to increase brand recognition and establishing partnerships in BRIC. Decrease in % due to leveraging of existing cost structure through economies of scale
Continued centralization of manufacturing and operations into the Burlington headquarter, supported by discontinuation of less profitable products, drives decrease in %
of sales. Partly offset by increased costs due to new market entries (regulatory ($5,000 - $50.000 per device), administrative, etc.)
Main focus of the R&D department is improving current products, rather than developing new ones, If we look at the last 4 years, LeMaitre had lower R&D costs
(going from 8% of sales to 7%) than its peers (9% every year). Thus, to sustain portfolio expansion, we fixed a target of 8% for 2022, which is closer to the market average
The new trend will be driven mainly by the improvement of the Accounts Payable and Inventory items, as they are influenced by the new negotiations with suppliers and a
more efficient inventory management. As we expect that the company will be able to increase Accounts Payable days by 3 and decrease Inventory days by 10 each year
Source: Operating Model, LBO Model, Bloomberg and Annual Report






2012 2013 2014 2015 2016 2017
CAGR    
12-17
2018 2019 2020 2021 2022 2023 2024
CAGR   
17-24
Gross Profit 41 45 48 54 63 71 82 94 105 117 129 143 155
(Gross margin) 72% 70% 68% 69% 71% 70% 69% 69% 70% 70% 70% 70% 70%
Selling & Marketing costs 21 22 22 23 26 28 32 35 39 42 46 51 56
(in % of Sales) 37% 34% 31% 29% 29% 28% 27% 26% 26% 25% 25% 25% 26%
General & Administrative costs 11 13 14 14 14 15 17 18 19 20 22 23 25
(in % of Sales) 19% 19% 20% 18% 16% 15% 14% 13% 13% 12% 12% 11% 11%
Research & Development costs 5 5 5 5 6 7 9 10 11 13 15 16 18
(in % of Sales) 9% 8% 7% 7% 7% 7% 7% 7% 7% 8% 8% 8% 8%
EBITDA 6 7 11 15 18 25 29 35 42 48 54 60 66
(in % of Sales) 11% 11% 15% 19% 20% 24% 24% 26% 28% 29% 29% 30% 30%
Working Capital 15 18 21 22 25 28 31 35 37 39 41 43 45
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LeMaitre’s key drivers for growth in the operational model are geographic 
expansion, organic growth and non-organic investments
EBITDA evolution 2017 - 2024
▪ EBITDA is expected to grow from $24.7 to
$65.7, representing an increase of 500bps
in the EBITDA margin (24.5% in 2024 vs
29.7% in 2017)







2017E 2018E 2019E 2020E 2021E 2022E 2023E 2024E
Revenue Forecast per Segment
Open non-biological Open biological
Endovascular & Others
Open non-biological: Organic CAGR: 7%
▪ Increase pricing power due to brand
recognition and reputation
▪ Portfolio enhancements due to high R&D
expertise
Open biological: Organic CAGR: 13%
▪ Increased production capacity in Burlington
▪ Further market share gains in leading
products, then growth rates will decrease. A
boost on volume is expected in Asia
Endovascular: Organic CAGR: 10%
▪ Volume will be the main driver of sales
▪ Less pricing power in the beginning but
afterwards it will increase due to higher
brand reputation. Growth will be in Line
with the market.
Open non-biological: ~$0.71M per year
▪ Punctual acquisitions to ensure market
leadership (2019 and 2023,
representing 3% growth in each year)
Open biological: ~$0.29M per year
▪ Acquisition in 2021 to update portfolio
with innovative products to expand
market leadership position
Endovascular: ~$1.57M per Year
▪ To gain momentum and as new
product-segment entrants, high
quality product lines’ acquisitions will
take place in 2018 and the two
following years
▪ Sales CAGR per region :
▪ Americas: 11%
▪ Europe: 10%
▪ Asia & Pacific: 22%
▪ RoW: 8%
▪ Significant sales increase due to:
▪ Entrance into new markets (South Africa, 
India, Brazil and Russia)
▪ Endovascular and biological (e.g. 
XenoSure) products approval
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▪ Total revenue CAGR is expected to be ~12%
▪ Take advantage on economies of scale, namely
in Biologics after manufacturing capacity increase
▪ Higher margin products
▪ Cost savings through centralization
▪ Leveraging existing cost structure by
expanding sales through higher cross-selling,
broader product portfolio and more efficient usage
of already existing sales infrastructure (e.g. Asia)
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LeMaitre is subject to a set of internal and external risks, some of which can be 
viewed as opportunities, and others should be subject to due dilligence







Mitigation / comfort 
▪ Acquisitions: Potential integration issues and lack of
market success of an acquired product line
▪ Thorough due diligence and integration plans
▪ Acquire approved products with successful track 
record
▪ Competition and substitution: Minimally invasive 
endovascular gaining higher share of overall surgeries 
▪ Inability to sustain high prices: Generic competition 
and pricing pressure
▪ Further diversification of product portfolio, including 
also endovascular products
▪ Constant innovation
▪ Ensure superiority of products and servicing
Operational
▪ Customer - The expansion of endovascular procedures
could lead interventional radiologists and cardiologists to
substitute vascular surgeons.
▪ Foster direct relationships with vascular surgeons
▪ Potentially expand direct sales efforts to 
interventional radiologists specialized in vascular 
surgery
▪ Sales representatives turnover
▪ Ensure talent retention through proper incentives
▪ Perform market research on regional distribution 
methods
Legal ▪ Product side effect liability
▪ From 2005 to 2016 LeMaitre was not subject to any 
material litigation, claims or assessments.
▪ Products non-approval or withdraw of major product-
line due to new legislation or regulation
▪ Revenues diversification achieved with the increase 
number of product lines and geographies
Regulatory
30Nova School of Business and Economics | Master in Finance | January 2018 | Private Equity Challenge | Group 1 | LeMaitre Vascular, Inc.
















2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Average Median 10Y Median 5Y Median
























Various valuation methods point towards an EV/EBITDA multiple of 13x – 14x as an 
appropriate entry price
▪ Currently trading comparables: 14 
companies were selected and divided 
into Global Multinational and Small 
Specialized segment (the later are the 
ones most similar to LeMaitre’s
business). (Median EV/SALES multiple 
of 3.8x)
▪ Preceding comparable transactions: 
Based on similar cardiovascular 
transactions occurred in the past 5 
years (Vascular Solutions is the most 
comparable transaction). (Median 
EV/SALES multiple of 3.05x)
▪ Comparables through-the-cycle: 
Median of the medians (same peer 
group) of the past 10 years in order to 
assess the economic cycle (Median 
EV/SALES multiple of 3.5x)
▪ DCF: Based on a DCF analysis, a 
multiple of 13.8x was computed based 
on future forecast
▪ LBO Model valuation: It was 
determined a maximum leverage of 6x 
EBITDA, assuming an entry and exit 



































































▪ We believe that an EV to EBITDA multiple of 13-14x is a
reasonable price to pay for LeMaitre, representing an EV to SALES
multiple of 3-4x
▪ The median EV/EBITDA multiple grew from 11x to 16.5x from
2007 to 2016, while the EV/SALES from 2.4x to 3.5x, respectively
▪ Given the current valuation premium to the historic median, the
Medical Device industry seems to be at a high point of its cycle
▪ Yet this overall multiple expansion is justified, as it is a growing
market (5-year CAGR 5%) with strong global growth expectations
▪ In case of an acquisition in the near future, we therefore assume a
multiple in the upper part of our range
▪ The EV/Sales ratio was not included in the Football Field, but its
results are in line with the EV/EBITDA










Note: Deep dive in valuation appendixes slides: calculations, EV/SALES graphs, vascular solutions deal
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French medical diagnostic group, owned by Private Equity
consortium – last refinancing in Sep 2017
Total leverage 8.0x, hereof 6.5x senior secured
Senior debt
Term loans at +300/ 350 bps [at 
launch in 2016: both +350bps]
Junior debt




Exceptionally high total leverage, 
market average ~6x
Favorable debt market conditions and LeMaitre’s strong cash generation profile 
allow for raising senior debt at spreads of ~325-375bps
Firm-specific determinant for default spread LeMaitre’s situation Impact on spread
Expected credit rating B2 (ICR >2.5 Y1, after >3) ~325-400 bps on average
Firm size Small: Market cap $ 600M Increases spread
Free Cash Flow conversion High with 77% (2016) Decreases spread
Volatility of cash flows Consistent, stable FCF growth Decreases spread
Management ownership (“skin in the game”) High executive ownership (20%) Decreases spread
Total leverage (after transaction) High: 6.0x EBITDA Increases spread
▪ LeMaitre should aim at raising
secured senior debt at rates of
LIBOR + 325-375bps in form of a
term loan
▪ The TLs will attract banks rather
than institutional investors due to
small tranche size. TLs should be
placed in European market, where
expected investor demand is high
▪ Low-interest rate environment has
led to decreasing yields and
credit spreads at historic lows
▪ Comparable LBO loan issuance of
Sebia shows high market appetite
for debt and low spreads (+300-
350 bps at B rating)
▪ Medical Device firms of similar
rating (B1-B2) to LeMaitre recently
issued term loans with spreads in
































n=24, BICS Medical Equipment & Device Manufacturing 
Recent comparable loan issuance
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The final capital structure with an initial leverage of 6.0x EBITDA maximizes 
returns and is deleveraged down to 1.2x EBITDA within 6 years









2018 2019 2020 2021 2022 2023
Deleveraging Profile 
Term Loan A Term Loan B






▪ 6 years at +350bps
▪ Mandatory repayment of 5-20% p.a. in Y1-Y5, final
bullet payment of 40% in Y6




▪ 7 years at +400bps
▪ Optional repayments of excess FCF (>$ 2M) each
year – no prepayment penalties






▪ 7 years at + 750bps
▪ 100% bullet payment at end of Y7





▪ Interest of +400bps
▪ Flat commitment fee
of 200bps
▪ Covering max. 40% of CAPEX needs of Y1-Y3





▪ $ 194M in total, representing ~56% of the capital structure
▪ Guaranteed rate of return (PIK) of 8% p.a.




▪ Total management ownership 18% ($ 0.9M) due to buy-in (see below): 0.4M




▪ High pre-deal management ownership (21% of shares outstanding)
▪ After-tax management proceeds from LBO amounting to $ 48M
▪ Reinvestment of 50% ($ 24M) into new capital structure assumed
▪ Most of buy-in through FRIs ($23M), remainder through ords ($ 1M)
Deleveraging 
and Refinancing
▪ Deleveraging to 1.1x EBITDA within 6 years through repayment of Term Loan A
and Term Loan B
▪ Rollover/refinancing of junior debt required in year 7
* Reference for the quoted interest rate spreads is the US 12M LIBOR; **Debt has ben assessed by 
BNP Paribas and reflects current market dynamics 
Sources $M x EBITDA Uses of Funds $M
Senior Debt 111.3
Term Loan A 37.1 1.5x EBITDA 2017 24.7
Term Loan B 74.2 3.0x EV/EBITDA Multiple 13.5
Junior Debt 37.1
Second-lien loan A 37.1 1.5x
Total Debt 148.5 6.0x Enterprise Value 334.0
Institutional Equity 175.1 Fees 13.4
Fixed Return Instrument 171.0 6.9x Advisory Fees 3.3
Ordinary Equity 4.1 0.2x Legal Fees 3.3
Management Equity 23.9 Transaction Fees 6.7
Fixed Return Instrument 22.9 0.9x
Sweet Equity 0.4 0.0x
Ords. From Instit. Strip 0.5 0.0x
Total Equity 198.9 8.0x
Total sources 347.4 14.0x Total uses 347.4
$M
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Total equity value creation is $445M generated from:
▪ Organic revenue growth by 50% (10.8% CAGR 17-22)
▪ Cash generation/ deleveraging by 13%
▪ Margin expansion by 26%
▪ Non-organic revenue growth by 11%


















12.5 26.2% 24.8% 23.3%
13 25.5% 24.2% 22.8%
13.5 25.0% 23.7% 22.3%
14 24.5% 23.3% 21.9%













le 12.5 26.2% 27.3% 28.4% 29.4% 30.4%
13 24.4% 25.5% 26.6% 27.6% 28.6%
13.5 22.9% 23.9% 25.0% 26.0% 27.0%
14 21.4% 22.4% 23.5% 24.5% 25.4%
14.5 20.0% 21.1% 22.1% 23.1% 24.0%
2018 2019 2020 2021 2022 2023 2024
Interest Coverage Ratio 2.3 2.8 3.3 4.0 4.9 7.2 8.1
Net Senior debt/EBITDA 3.4x 2.6x 1.9x 1.4x 0.9x 0.5x 0.5x
Net Total debt/EBITDA 5.0x 4.0x 3.2x 2.4x 1.7x 1.1x 0.5x
EBITDA/Cash interest 2.8x 3.3x 3.9x 4.8x 5.9x 9.0x 10.3x
FCF/(Cash interest+Debt Repayment)* 1.2x 1.3x 1.4x 1.4x 1.7x 1.2x 0.4x
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▪ Open Biological and Endovascular space are
growing fast and LeMaitre can take a higher share of
that growth, namely in Asia and the BRICs
▪ Some products might get approvals sooner than
expected, namely in Asia
▪ Partnerships are more profitable due to lower than
expected costs and faster sales ramp-up
▪ SG&A costs increase in absolute terms, but EBITDA
margins improve due to higher sales and increased
brand recognition creating economies of scale
CAGR 17-22 Value 2022
Revenue 13.9% $ 194M
Gross profit 14.2% $ 138M
EBITDA 19.1% $ 59M
Financial performance is contingent on several internal and market-related 
external factors
Bank case Investment case Optimistic case 
▪ Slower adoption of Biologic devices internationally
than foreseen, driven also by delayed regulatory
approvals
▪ Adoption and scaling of acquired endovascular
devices takes longer than expected
▪ Pressure on gross margins, as price increases
outside US cannot be sustained to full extent
▪ Centralization of operations leads to less G&A cost
declines than expected
▪ EBITDA margin improvement through economies of
scale less material due to slower sales increase
CAGR 17-22 Value 2022
Revenue 10.0% $ 163M
Gross profit 9.5% $ 112M
EBITDA 11.5% $ 43M
CAGR 17-22 Value 2022
Revenue 12.7% $ 184M
Gross profit 12.7% $ 129M















FRI $ 31M $ 34M $ 34M 
Ords $ 37M $ 64M $ 79M 
Total $ 68M $ 98M $ 113M 
Institution
(Entry $175M)
MM 2.3x 3.0x 3.4x
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A strategic sale to a Medtech leader is the best exit option for LeMaitre to 
guarantee its intended exit multiple of 13.5x 
Potential acquirers
LeMaitre specific: Over the past years, the healthcare industry as a whole has experienced an abundance of mergers and acquisitions → major players are buying
up their peers. This trend makes a trade sale an attractive exit for LeMaitre
PE specific: provides a complete and immediate exit; negotiations take place with a single buyer allowing for a quicker and more efficient process; not subject to the
regulatory restrictions applicable to IPOs; may obtain a higher value for the company thanks to potential synergies
Medtronic is a global healthcare solutions
company, covering: Cardiac and vascular,
Minimally Invasive and Restorative Therapies and
Diabetes Group







Baxter primarily focuses on products to
treat hemophilia, kidney disease, immune
disorders and other chronic and acute medical










Teleflex is a global provider of medical
technologies with solutions in the fields of
vascular and interventional access, surgical,
anesthesia, cardiac care, urology, emergency
medicine and respiratory care
Trade sale exit strategy
Comparable transactions Comparable transactions Comparable transactions
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In LeMaitre’s case, thorough commercial Due Diligence is imperative in order to 
prove the Investment Thesis 



















































Inventory and supply 
chain processes
Outlook for open vascular 
market
▪ Competitor analysis on product line level
▪ Confirm LeMaitre‘s differentiation and quality on product line level
▪ Shortlist of potential M&A targets matching criteria checklist
▪ Evaluate, if these are available at prices affordable for LeMaitre
▪ Evaluate entry barriers into planned expansion territories
▪ Analyze local competition, pricing, regulatory hurdles etc.
▪ Assess LeMaitre‘s international brand recognition and reputation
▪ Analyze pricing power and industry developments abroad
▪ Evaluate dependence of sales on personal relationships
between doctors and specific sales representatives
▪ Deep analysis of international regulatory standards
▪ Assess likelihood of planned international approvals
▪ Identify expected regulatory and legislative changes and trends
▪ Create scenarios of potential effects on LeMaitre‘s sales
▪ Analyze potential of further expansion and integration of further
product lines into main facility
▪ Review supplier relationships and compare to industry standards
▪ Analyze supply chain and identify ideal inventory level
▪ Verify assumption of stable market outlook and continued need
of open vascular surgery
▪ Lack of differentiation and/or superior
quality compared to competitor products
▪ Lack of potential, affordable targets to
pursue acquisition strategy
▪ Low probability of successful expansion
into target markets in near future
▪ Lack of brand recognition abroad and thus
no pricing power
▪ High dependence on persons, risk of
sales loss in case of sales rep turnover
▪ Low probability of major expected
approvals (e.g. Biologics in Asia)
▪ High risk of major decrease in
reimbursement of LeMaitre products
▪ Maximum capacity reached, impeding
further centralization of operations
▪ Low chance of improving supplier contracts
▪ Planned decrease of inventory not feasible
▪ Moderate to high probability of strong
decline in open vascular surgeries
Importance
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LeMaitre should be acquired by a multiple of 13.5x EBITDA, can be leveraged up to 
6x EBITDA and will be an attractive strategic target after 5 years
Investment rationale
▪ Outstanding financials: EBITDA grew from $6M to $25M,
from 2012 to 2017, with high cash conversion
▪ Growing market: The PVD market is expected to grow from
$3.5B to 5.9B, between 2012 to 2022
▪ Sustainable competitive advantage: A unique niche
strategy, market-leading products and a successful direct
sales force are defendable differentiation factors
Growth strategy
▪ Entry multiple between 13-14.5x EV/EBITDA
▪ Strong cash generation and debt market conditions
allow for raising senior debt at spreads of ~325-375bps
▪ The TLs will attract banks due to small tranche size
and will be placed in European market
▪ The final capital structure maximizes returns and is
deleveraged down to 1.1x EBITDA within 6 years
▪ Portfolio expansion: Strategic expansion, namely into the
endovascular segment, through a focused acquisition
strategy of adjacent product lines (~1 per year)
▪ International strategy: Further increase of the TAM through
wholistic internationalization strategy, aiming at increasing
geographic reach and creating cross-selling opportunities
▪ Optimization of operations: Continued centralization of
operations, more efficient usage of international structures
and working capital optimization leading to further


















12.5 26.2% 24.8% 23.3%
13 25.5% 24.2% 22.8%
13.5 25.0% 23.7% 22.3%
14 24.5% 23.3% 21.9%
14.5 24.0% 22.8% 21.5%
Deal structuring
▪ In 2022, LeMaitre is still the undisputed global
leader in the open vascular space
▪ Due to its growing endovascular portfolio, they
are now present in all major segments of the
PVD market and cater to a much higher TAM
▪ LeMaitre will have its direct sales force present
in all major PVD markets, including Asia and the
BRIC
▪ This unique positioning makes LeMaitre an
ideal strategic target for a Medtech multinational
▪ A sale to a strategic buyer is therefore the best
exit option with an intended exit multiple of 13.5x
▪ Returns reflects an attractive IRR of 25% and an
MM of 3.0x





Term Loan B, 3x
Term Loan A, 1.5x
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